Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020

Details

• Alternative Title:
  J Infect Dis
• Personal Author:
  Pathela, Preeti ; Crawley, Addie ; Weiss, Don ; Maldin, Beth ; Cornell, Jennifer ; Purdin, Jeff ; Schumacher, Pamela K ; Marovich, Stacey ; Li, Joyce ; Daskalakis, Demetre
• Corporate Authors:
  NYC Serosurvey Team
• Description:
  Background
  
  New York City (NYC) was the U.S. epicenter of the Spring 2020 COVID-19 pandemic. We present seroprevalence of SARS-CoV-2 infection and correlates of seropositivity immediately after the first wave.
  
  Methods
  
  From a serosurvey of adult NYC residents (May 13-July 21, 2020), we calculated the prevalence of SARS-CoV-2 antibodies stratified by participant demographics, symptom history, health status, and employment industry. We used multivariable regression models to assess associations between participant characteristics and seropositivity.
  
  Results
  
  Seroprevalence among 45,367 participants was 23.6% (95% CI, 23.2%-24.0%). High seroprevalence (>30%) was observed among Black and Hispanic individuals, people from high poverty neighborhoods, and people in health care or essential worker industry sectors. COVID-19 symptom history was associated with seropositivity (adjusted relative risk=2.76; 95% CI, 2.65-2.88). Other risk factors included sex, age, race/ethnicity, residential area, employment sector, working outside the home, contact with a COVID-19 case, obesity, and increasing numbers of household members.
  
  Conclusions
  
  Based on a large serosurvey in a single U.S. jurisdiction, we estimate that just under one-quarter of NYC adults were infected in the first few months of the COVID-19 epidemic. Given disparities in infection risk, effective interventions for at-risk groups are needed during ongoing transmission.
• Subjects:
  • Major Article
  • AcademicSubjects/MED00290
  • SARS-CoV-2
  • seroprevalence
  • seroepidemiology
• Source:
  J Infect Dis. 2021;
• Pubmed ID:
  33836067
• Pubmed Central ID:
  PMC8083309
• Document Type:
  Journal Article
• Download URL:
  https://stacks.cdc.gov/view/cdc/107346/cdc_107346_DS1.pdf
• File Type:
  [PDF - 943.64 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:b8e70569269c6186a94cb17acb66aadf8e3acbba843e4da2dc9814c088ba14f4